Global Medical Cannabis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Medical Cannabis Market Analysis

The medical cannabis market has experienced significant growth in recent years, driven by increasing recognition of its therapeutic benefits for various medical conditions. With legalization efforts gaining momentum across multiple regions, the demand for medical cannabis products is on the rise. This market encompasses a wide range of products, including oils, capsules, and edibles, tailored for conditions such as chronic pain, epilepsy, and mental health disorders. Recent developments, such as advancements in cultivation techniques and extraction processes, have improved product quality and efficacy, further fueling market expansion. In addition, growing consumer awareness and acceptance, coupled with supportive government policies, are key factors contributing to the market's positive outlook. As research continues to unveil the potential benefits of cannabis, the medical cannabis market is poised for sustained growth, offering new opportunities for pharmaceutical companies and healthcare providers alike.

Medical Cannabis Market Size

The global medical cannabis market size was valued at USD 21.06 billion in 2023 and is projected to reach USD 108.90 billion by 2031, with a CAGR of 22.80% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Medical Cannabis Market Trends

“Demand for Personalized Cannabis Products”

The medical cannabis market is witnessing transformative trends driven by innovation and evolving consumer preferences. A notable trend is the growing demand for personalized cannabis products, where consumers seek tailored formulations to address specific health conditions and individual needs. Innovations in cannabis extraction and formulation techniques are enabling the development of diverse product offerings, such as targeted oils and infused edibles, that enhance therapeutic effects. In addition, advancements in technology, including the use of artificial intelligence and data analytics in cultivation and supply chain management, are optimizing production processes and ensuring product consistency. Overall, these trends reflect a shift towards more effective, customized medical cannabis solutions, catering to the diverse needs of patients and driving market growth.

Report Scope and Medical Cannabis Market Segmentation  

医用大麻市场定义

医用大麻是指将大麻植物及其衍生物用于治疗目的。它包括各种产品，包括油、胶囊、酊剂和外用制剂，其中含有四氢大麻酚 (THC) 和大麻二酚 (CBD) 等大麻素。医用大麻用于缓解各种健康状况的症状，包括慢性疼痛、癫痫、多发性硬化症、化疗引起的恶心和焦虑。其使用通常受不同地区法律的管制，通常在常规治疗无效时建议使用。

医用大麻市场动态

驱动程序

• 提高接受度和合法化

医疗专业人士和医用大麻患者对医用大麻的接受度不断提高，这是市场增长的重要驱动力。随着研究不断揭示大麻素对各种疾病的治疗益处，医疗保健提供者更倾向于推荐大麻作为治疗选择。这种观念的转变提高了患者的认识，并愿意考虑使用医用大麻来治疗慢性疼痛、焦虑和其他疾病。此外，许多地区医用大麻的合法化进一步促进了其融入主流医疗保健。这一监管变化使其使用合法化，并鼓励对研究和产品开发的投资，从而扩大了市场。这些因素的综合作用预计将促进医用大麻市场的大幅增长。

•  慢性病患病率上升

癌症、癫痫和多发性硬化症等慢性病的发病率不断上升，对有效的疼痛管理和治疗解决方案的需求巨大，大大促进了医用大麻市场的发展。患有这些疾病的患者经常会经历剧烈的疼痛、不适和一系列令人衰弱的症状，而传统治疗方法可能无法充分解决这些问题。医用大麻含有多种大麻素，是一种可以缓解疼痛和改善生活质量的天然替代品。随着医疗保健提供者越来越认识到大麻治疗的潜力，越来越多的患者被推荐使用医用大麻作为一种可行的选择。这种日益增长的接受度，加上正在进行的研究证明大麻在缓解症状方面的有效性，继续推动市场增长，因为患者正在寻求有效和全面的方法来管理他们的健康状况。

机会

• 与传统医疗保健的整合

大麻公司与传统医疗保健提供商之间的合作为医用大麻领域的市场增长提供了重大机遇。通过与医疗保健专业人士合作，大麻公司可以提高其产品的合法性并培养潜在患者的信任。这些合作可以促进教育计划和临床指南的制定，使医疗保健提供商更愿意将大麻疗法作为综合治疗计划的一部分进行推荐。随着医疗保健提供商对医用大麻的功效和安全性越来越有信心，他们更有可能提倡使用大麻，最终增加患者获得这些疗法的机会。这种整合扩大了大麻产品的市场覆盖范围，并有助于主流医疗保健对医用大麻的整体接受，从而推动市场持续扩张。

• 研发进展

对大麻素治疗益处的持续研究为医用大麻市场带来了新机遇。随着科学家和医疗保健专业人士继续探索各种大麻素的药用特性，他们发现了从慢性疼痛和焦虑到神经系统疾病等各种疾病的创新应用。这项研究促成了新型医用大麻产品的开发，扩大了患者可用的治疗选择范围。这些进步满足了不同患者的需求，并提高了大麻疗法的疗效和安全性。随着越来越多的临床研究证实这些产品的益处，它们很可能会得到医疗保健提供者和患者的认可。产品供应的扩大为公司提供了一个有利可图的机会，使他们能够在不断增长的医用大麻市场中占据更大的份额，最终改善患者的治疗效果和满意度。

限制/挑战

• 缺乏标准化监管

由于缺乏标准化法规，且不同地区的法律框架各异，医用大麻市场面临巨大挑战。每个司法管辖区都有自己的医用大麻种植、分销和销售规则，这为企业创造了一个复杂的环境。这种监管不一致往往会导致新参与者的混乱和进入市场的延迟。公司可能花费大量时间和资源来了解当地法律、获得必要的许可证，并确保遵守不同的法规。这些障碍可能会阻碍潜在投资者并限制市场的增长。因此，缺乏统一的监管方法对全球医用大麻产品的扩张和可及性构成了重大挑战。

•  来自传统疗法的竞争

成熟的药物治疗继续占据医疗保健市场的很大份额，通常有广泛的研究、临床试验和监管部门的批准作为后盾。这些传统疗法被医疗保健专业人士广泛使用，长期以来一直以安全和有效而闻名。因此，患者和医生可能不愿意将医用大麻产品视为可行的替代品，尤其是在癌症和慢性疼痛等严重疾病中。尽管医用大麻有潜在的好处，但对传统药物的熟悉和信任可能会阻碍其应用。这种对成熟疗法的依赖限制了大麻疗法的市场增长，因为医疗保健专业人士可能会优先考虑熟悉的药物选择，而不是较新的、不太为人所知的大麻产品。这种限制给医用大麻市场带来了挑战，使其难以吸引患者和医疗保健提供者。

本市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需获取更多市场信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

医用大麻市场范围

市场根据产品、来源、种类、衍生物、应用、给药途径、治疗类型、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

产品

• 油
• 医用大麻胶囊
• 修补
• 整朵花
• 地花
• 电子烟
• 干燥医用大麻
• 面霜和保湿霜
• 面膜和精华液
• 洁面乳
• 其他的

来源

• 自然的
• 合成的

物种

• 印度大麻
• 大麻
• 杂交种

应用

• 阿尔茨海默病
• 食欲不振
• 癌症
• 炎症性肠病
• 饮食失调
• 癫痫
• 自闭症
• 心理健康状况
• 多发性硬化症
• 疼痛管理
• 恶心
• 肌肉痉挛
• 消瘦综合征（恶病质）
• 提升情绪
• 抑郁症和睡眠障碍
• 焦虑
• 其他的

衍生品

• 大麻二酚（CBD）
• 四氢大麻酚 (THC)/Delta-8-四氢大麻酚
• 大麻酚（CBN）
• 大麻环醇 (CBL)
• 大麻色烯 (CBC)
• 大麻萜酚（CBG）
• 其他的

治疗类型

• 祛痰药
• 抗病毒物质
• 镇痛药
• 春药
• 迷幻
• 其他的

给药途径

• 口服溶液和胶囊
• 吸烟
• 汽化器
• 专题
• 其他的

最终用户

• 制药行业
• 研发中心
• 家庭护理环境
• 医院
• 康复中心
• 其他的

分销渠道

• B2B
• B2C

 医用大麻市场区域分析

对市场进行分析，并按国家、产品、来源、物种、衍生物、应用、给药途径、治疗类型、最终用户和分销渠道提供市场规模洞察和趋势。

市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

North America is expected to dominate the global medical cannabis market due to the increasing investment in medical cannabis. The U.S. is expected to dominate the North America region due to the legalization of medical cannabis use. Germany is expected to dominate the Europe region due to the increasing demand for medical cannabis in emerging markets and expansion. Australia is expected to dominate the Asia-Pacific region due to the presence of key manufacturers and advanced technological processes.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Medical Cannabis Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Medical Cannabis Market Leaders Operating in the Market Are:

• MediPharm Labs Inc. (Canada)
• Tilray (Canada)
• Aurora Cannabis (Canada)
• JAZZ Pharmaceuticals Inc. (U.K.) (GW Pharmaceuticals plc)
• HEXO Corp. (Canada) (Zenabis Global Ltd)
• Cresco Labs (U.S.)
• Peace Naturals Project Inc. (Canada)
• CANOPY GROWTH CORPORATION (Canada)
• Medical Marijuana, Inc. (U.S.)
• Seed Cellar (U.S.)
• EcoGen Biosciences (U.S.)
• CANNABIS SEEDS USA (U.S.)
• Seeds For Me (U.S.)
• HUMBOLDT SEED COMPANY (U.S.)
• Extractas (U.S.)
• World Class Cannabis Seeds (Crop King Seeds) (Canada)
• BARNEY'S FARM (Netherlands)
• FOLIUM BIOSCIENCES (U.S.)
• PharmaHemp (U.K.)
• Elixinol Global Limited (Australia)
• ENDOCA (Netherlands)
• Harmony (U.K.)
• MARY’S Nutritionals, LLC (U.S.)
• Pure Ratios (U.S.)
• Greenwich Biosciences, Inc. (U.S.)
• Upstate Elevator Supply Co. (U.S.)
• Apothecanna (U.S.)
• BOL Pharma (Israel)
• IDT Australia (Australia)

Latest Developments in Medical Cannabis Market

• In February 2023, Aurora Cannabis Inc., a Canadian company specializing in global cannabis distribution, collaborated with MedReleaf Australia to launch CraftPlant, a new medical cannabis brand for the Australian market. The initial offerings from CraftPlant include three products—Greendae, Navana, and HiVolt—all of which are now available for prescription by doctors. Each strain boasts a high THC concentration and is sourced from premium cultivars developed by Occo, Aurora's leading scientific and genetics company, and will be packaged in 10g canisters produced under strict EU-GMP authorized standards
• In July 2023, Carer, an oncology company in India, announced a partnership with Wholeleaf, a certified manufacturer of medicinal cannabis and cannabidiol. This collaboration aims to improve the overall well-being of cancer patients by offering comprehensive support that includes nutrition for caregivers, physical therapy, and mental health services. With official approval from the Ayush ministry to manufacture and market its products nationwide, CARER and Wholeleaf are combining their services to deliver a holistic solution for cancer care
• In September 2023, Alternaleaf, a clinic recognized for helping Australians obtain medicinal cannabis, announced its expansion into the United Kingdom. Research indicates that England is on track to become the second-largest market for medicinal cannabis in Europe, driven by growing demand. With over 360,000 reported cases of opioid addiction in the UK, experts suggest that medicinal cannabis could serve as a viable alternative to opioids, which are frequently prescribed unnecessarily
• In April 2022, Medi Cane Health Inc. and Dr. Reddy's Laboratories Ltd. launched their medical cannabis product in Germany. This collaboration aims to meet the growing demand for medical cannabis solutions in the region. The introduction of this product marks a significant step in expanding access to therapeutic cannabis options for patients in Germany
• In April 2022, New York City witnessed its first legal marijuana sales, occurring just a month after seven medical marijuana businesses received approval to sell their products to all adults. This milestone signifies a significant shift in the state's cannabis landscape, expanding access beyond medicinal use. The initiative aims to create a regulated market while benefiting local economies and ensuring consumer safety

SKU-52961